The covid program obviously made up for the hit to the HBV program. Nice to have multiple shots on goal. They do need one to pan out though but the covid protease always had better odds of success than HBV programs even though earlier in development IMO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.